![rapt therapeutics stock forecast rapt therapeutics stock forecast](https://cdn.snapi.dev/images/v1/b/w/conf14-866256.jpg)
Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. and changed its name to RAPT Therapeutics, Inc. stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock.
![rapt therapeutics stock forecast rapt therapeutics stock forecast](https://3ts7jc2y8bhe2khfj03ct3q2-wpengine.netdna-ssl.com/wp-content/uploads/2021/06/image-174-1024x518.png)
The company was formerly known as FLX Bio, Inc. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues.
#RAPT THERAPEUTICS STOCK FORECAST FULL#
Use the PitchBook Platform to explore the full profile. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. RAPT Therapeutics (RAPT-17.9) has recorded its biggest intraday loss since November 2020 on below-average volume as the clinical-stage biotech prepares for a presentation at a major healthcare. Information on stock, financials, earnings, subsidiaries, investors, and executives for RAPT Therapeutics. This suggests a possible upside of 162.8 from the stock's current price.
![rapt therapeutics stock forecast rapt therapeutics stock forecast](https://investorplace.com/wp-content/uploads/2021/06/astronaut-on-pencil.png)
On average, they anticipate RAPT Therapeutics' share price to reach 60.29 in the next twelve months. Their forecasts range from 49.00 to 72.00. (NASDAQ:RAPT) RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. 7 Wall Street analysts have issued twelve-month target prices for RAPT Therapeutics' stock.